加味川芎茶调散联合风池穴温通针法治疗无先兆偏头痛的疗效观察及脑fMRI研究

注册号:

Registration number:

ITMCTR2025000841

最近更新日期:

Date of Last Refreshed on:

2025-04-24

注册时间:

Date of Registration:

2025-04-24

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

加味川芎茶调散联合风池穴温通针法治疗无先兆偏头痛的疗效观察及脑fMRI研究

Public title:

Therapeutic efficacy of jiawei Chuanxiong chatiao san and Fengchi acupoint with Wentong acupuncture in the treatment of migraine without aura and fMRI study of brain

注册题目简写:

English Acronym:

研究课题的正式科学名称:

加味川芎茶调散联合风池穴温通针法治疗无先兆偏头痛的疗效观察及脑fMRI研究

Scientific title:

Therapeutic efficacy of jiawei Chuanxiong chatiao san and Fengchi acupoint with Wentong acupuncture in the treatment of migraine without aura and fMRI study of brain

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘雪颖

研究负责人:

赵永烈

Applicant:

Liu Xueying

Study leader:

Zhao Yonglie

申请注册联系人电话:

Applicant telephone:

+86 15562509902

研究负责人电话:

Study leader's telephone:

+86 13641086409

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lxy971216@163.com

研究负责人电子邮件:

Study leader's E-mail:

yongy3@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号北京中医药大学

研究负责人通讯地址:

北京市朝阳区安定门外小关街51号

Applicant address:

No. 11 Bei San Huan Dong Lu Chaoyang District Beijing China

Study leader's address:

No.51 Xiaoguan Street Andingmenwai Chaoyang District Beijing China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学

Applicant's institution:

Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BZYSY-2025KYKTPJ-08

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

北京中医药大学第三附属医院科研伦理委员会

Name of the ethic committee:

IRB of The third Hospital affiliated to Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/27 0:00:00

伦理委员会联系人:

赵莹

Contact Name of the ethic committee:

Zhao Ying

伦理委员会联系地址:

北京市朝阳区安定门外小关街51号

Contact Address of the ethic committee:

No.51 Xiaoguan Street Andingmenwai Chaoyang District Beijing China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8498 5602

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zydsyec2023@126.com

研究实施负责(组长)单位:

北京中医药大学第三附属医院

Primary sponsor:

Beijing University of Chinese Medicine Third Affiliated Hospital

研究实施负责(组长)单位地址:

北京市朝阳区安定门外小关街51号

Primary sponsor's address:

No.51 Xiaoguan Street Andingmenwai Chaoyang District Beijing China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学第三附属医院

具体地址:

北京市朝阳区安定门外小关街51号

Institution
hospital:

Beijing University of Chinese Medicine Third Affiliated Hospital

Address:

No.51 Xiaoguan Street Andingmenwai Chaoyang District Beijing China

经费或物资来源:

首都卫生发展科研专项

Source(s) of funding:

Capitals Funds for Health Improvement and Research

研究疾病:

无先兆偏头痛

研究疾病代码:

Target disease:

Migraine without aura

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评估风池穴温通针法、加味川芎茶调散以及两者联合治疗无先兆偏头痛的有效性及安全性,明确并示范推广针对无先兆偏头痛的临床治疗优化方案。

Objectives of Study:

To evaluate the efficacy and safety of the Wentong acupuncture at Fengchi acupoint Modified Chuanxiong Chatiao San and their combination in the treatment of migraine without aura and to clarify and demonstrate the promotion of the optimized clinical treatment plan for migraine without aura.

药物成份或治疗方案详述:

加味川芎茶调散(基本组成:生川芎 30g,荆芥 12g,防风 5g,羌活 6g,白芷 6g,细辛 3g,薄荷 24g,甘草 6g,柴胡 12g,白芍 30g,当归 15g)每次将一袋颗粒加水200ml溶解,早晚饭后一小时服用,连续用药4周; 在风池穴施以温通针法,双侧施针,左右交替进行,每周治疗1次,连续治疗4周。

Description for medicine or protocol of treatment in detail:

Modified Chuanxiong Chatiao San (Basic composition: 30g of raw Chuanxiong 12g of Jingjie 5g of Fangfeng 6g of Qianghuo 6g of Baizhi 3g of Xixin 24g of Bohe 6g of Gancao 12g of Chaihu 30g of Baishao 15g of Danggui). Dissolve one bag of granules in 200ml of water each time and take it one hour after breakfast and dinner. Take the medicine continuously for 4 weeks. Wentong acupuncture is applied at the Fengchi acupoints bilaterally with the needles alternated on the left and right sides. The treatment is given once a week for 4 consecutive weeks.

纳入标准:

(1)临床症状符合无先兆偏头痛的诊断标准; (2)年龄在18-65周岁,性别不限,右利手; (3)首次发病年龄<50岁,病程≥1年; (4)近3个月平均每月头痛发作天数为2-14天; (5)研究参与者头痛发作为中重度疼痛(VAS平均得分4~10分); (6)能够签署知情同意,填写头痛日记,且配合完成治疗及随访者。

Inclusion criteria

(1) Clinical symptoms meeting the diagnostic criteria for migraine without aura; (2) Age between 18-65 years old gender-neutral right-handed; (3) Age of first attack <50 years duration of disease ≥1 year; (4) The average number of headache attack days per month in the last 3 months was 2-14 days; (5) Study participants with headache attacks of moderate to severe pain (mean VAS score of 4-10); (6) Those who were able to sign the informed consent fill in the headache diary and cooperated in completing the treatment and follow-up visits.

排除标准:

(1)合并其他原发性头痛、继发性头痛及其他诊断不明的头痛者; (2)合并有心脑血管、肝、肾和造血系统等严重原发性疾病及其他器质性病变者; (3)确诊有严重精神障碍者,如精神分裂症、分裂情感性障碍、偏执性精神病、双相情感障碍、癫痫所致精神障碍、精神发育迟滞伴发精神障碍等; (4)存在智力障碍不能配合完成问卷者; (5)哺乳期妇女、妊娠或计划妊娠者; (6)长期服用止痛药或止痛药依赖者(1个月内服用15天以上止痛药); (7)4周内服用过有明确偏头痛预防性治疗效果的药物者; (8)对本研究所用中药配方颗粒中任何一种成分过敏或不能接受针刺者; (9)3个月内参加过偏头痛预防性治疗的相关临床研究者。 (10)有MRI禁忌症:心脏起搏器、幽闭恐惧症等; (11)有任何颅骨畸形及颅内病变者。

Exclusion criteria:

(1) Combined with other primary headache secondary headache and other headache with unknown diagnosis; (2) Those who have a combination of serious primary diseases such as cardiovascular cerebrovascular hepatic renal and hematopoietic systems and other organic lesions; (3) Those with confirmed diagnosis of serious mental disorders such as schizophrenia schizoaffective disorder paranoid psychosis bipolar disorder mental disorder due to epilepsy mental retardation with mental disorder etc; (4) Those with intellectual disabilities who cannot cooperate in completing the questionnaire; (5) Nursing women pregnant or planning to be pregnant; (6) Those who have been taking painkillers for a long time or those who are dependent on painkillers (taking painkillers for more than 15 days in 1 month); (7) Those who have taken medications with clear prophylactic therapeutic effects for migraine within 4 weeks; (8) Those who are allergic to any of the ingredients in the Chinese medicine formula granules used in this study or cannot accept acupuncture; (9) Those who have participated in a clinical study related to migraine preventive treatment within 3 months. (10) Have contraindications to MRI: pacemaker claustrophobia etc; (11) Those with any cranial deformity and intracranial lesions.

研究实施时间:

Study execute time:

From 2024-01-01

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-05-01

To      2026-12-31

干预措施:

Interventions:

组别:

温通针药组

样本量:

38

Group:

Wentong Acupuncture and Medicine Group

Sample size:

干预措施:

温通针法针刺风池穴和口服加味川芎茶调散

干预措施代码:

Intervention:

Wentong Acupuncture at the Fengchi point and oral Modified Chuanxiong Chatiao San

Intervention code:

组别:

温通针刺组

样本量:

38

Group:

Wentong Acupuncture Group

Sample size:

干预措施:

温通针法针刺风池穴

干预措施代码:

Intervention:

Wentong Acupuncture at the Fengchi point

Intervention code:

组别:

温通中药组

样本量:

38

Group:

Wentong Medicine Group

Sample size:

干预措施:

口服加味川芎茶调散

干预措施代码:

Intervention:

oral Modified Chuanxiong Chatiao San

Intervention code:

组别:

对照组

样本量:

38

Group:

Control Group

Sample size:

干预措施:

口服加味川芎茶调散模拟剂

干预措施代码:

Intervention:

Oral Modified Chuanxiong Chatiao San simulant

Intervention code:

样本总量 Total sample size : 152

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学第三附属医院

单位级别:

三甲

Institution/hospital:

Beijing University of Chinese Medicine Third Affiliated Hospital

Level of the institution:

Tertiary hospital

测量指标:

Outcomes:

指标中文名:

不良事件发生率

指标类型:

副作用指标

Outcome:

Adverse Event Incidence Rate

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝肾功

指标类型:

副作用指标

Outcome:

Liver and kidney function test

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

经络检测指标

指标类型:

附加指标

Outcome:

Meridian Detection Indicators

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头痛影响测评量表

指标类型:

次要指标

Outcome:

Headache Impact Test (HIT-6)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗应答率

指标类型:

次要指标

Outcome:

Response rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

偏头痛特异性生活质量问卷

指标类型:

次要指标

Outcome:

Migraine-Specific Quality-of-Life Questionnaire(MSQ)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经影像学指标

指标类型:

附加指标

Outcome:

Neuroimaging indicators

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性止痛药物治疗次数

指标类型:

次要指标

Outcome:

Acute analgesic drug treatment frequency

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

偏头痛发作持续时间

指标类型:

次要指标

Outcome:

Migraine Duration

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

参与者接受干预的动机与期望

指标类型:

附加指标

Outcome:

Participants' motivations and expectations for receiving the intervention

Type:

Additional indicator

测量时间点:

测量方法:

访谈

Measure time point of outcome:

Measure method:

interview

指标中文名:

血常规

指标类型:

副作用指标

Outcome:

Blood Routine Test

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医院焦虑和抑郁量表

指标类型:

次要指标

Outcome:

Hospital anxiety and depression scale(HADS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

次要指标

Outcome:

visual analogue scale(VAS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

参与者的体验与反馈

指标类型:

附加指标

Outcome:

Participants' experiences and feedback

Type:

Additional indicator

测量时间点:

测量方法:

访谈

Measure time point of outcome:

Measure method:

interview

指标中文名:

生物学指标

指标类型:

附加指标

Outcome:

Biological indicators

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

参与者依从性

指标类型:

附加指标

Outcome:

Participant compliance

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

偏头痛工作效率和活动障碍问卷

指标类型:

次要指标

Outcome:

Work Productivity and Activity Impairment Questionnaire:Migraine(WPAI)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

偏头痛发作天数

指标类型:

主要指标

Outcome:

Migraine Days

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

偏头痛发作次数

指标类型:

次要指标

Outcome:

Migraine Attacks

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用区组随机化方法,随机序列由不参与本研究统计分析工作的统计人员采用SAS软件,样本按组别代码,温通针药组:温通针刺组:温通中药组:对照组=1:1:1:1的比例产生。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study adopts the block randomization method. The random sequence is generated by statisticians who are not involved in the statistical analysis of this study using the SAS software. The samples are generated in the proportion of the Wentong Acupuncture and Medicine Group: the Wentong Acupuncture Group: the Wentong Medicine Group: the Control Group = 1:1:1:1 according to the group code.

盲法:

本研究中针刺干预难以实现盲法,但研究药物可以通过制备与其外观、色泽、口味、气味上相一致的模拟剂来实现盲法。对每个研究对象设置药物设盲编码,并在分发药品外包装上标记,根据随机化分组结果由与本研究无关人员在贴有设盲编码的药品包装内分别装入试验药物或安慰剂。盲底密封,由统计学家与主要研究者存底。

Blinding:

In this study, it is difficult to achieve blinding in acupuncture intervention, but blinding can be achieved for the study drug by preparing a placebo that is consistent with the appearance, color, taste, and smell of the drug. A blinding code is set for each study subject, and it is marked on the outer packaging of the distributed drugs. According to the randomization grouping results, an individual unrelated to this study will separately load the experimental drug or placebo into the drug packaging with the blinding code. The blind code is sealed and kept by the statistician and the main researcher.

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统